Smooth sailing for NeuroDiscovery
Tuesday, 22 July, 2008
Perth biotech NeuroDiscovery has successfully completed an early stage trial of its neuropathic pain candidate NSL-043.
The compound, previously developed by another company for inflammatory disease, was successful in single ascending dose clinical trials and has now completed a multiple ascending dose trail.
The company said the compound's adverse event profile demonstrated good safety and tolerability.
NeuroDiscovery is also investigating the development of antagonists of the connexin and pannexin families of gap junction proteins.
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
